{"id":"albutrepenonacog-alfa","rwe":[{"pmid":"40176382","year":"2025","title":"Performance of a Drug-Specific Calibration Curve for Monitoring Treatment With Albutrepenonacog Alfa: A Multicenter Study in Argentina.","finding":"","journal":"International journal of laboratory hematology","studyType":"Clinical Study"},{"pmid":"38070040","year":"2024","title":"Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.","finding":"","journal":"Advances in therapy","studyType":"Clinical Study"},{"pmid":"37680021","year":"2023","title":"Benefits of rIX-FP prophylaxis in patients with Haemophilia B: real-world evidence from a Spanish reference centre.","finding":"","journal":"Hematology (Amsterdam, Netherlands)","studyType":"Clinical Study"},{"pmid":"37522479","year":"2023","title":"Switching and increasing prophylaxis regimen with a genetically recombinant fusion of coagulation factor IX and albumin in haemophilia B: a case report.","finding":"","journal":"Current opinion in hematology","studyType":"Clinical Study"},{"pmid":"37323270","year":"2023","title":"Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa (rIX-FP): A case report.","finding":"","journal":"Clinical case reports","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Hereditary factor IX deficiency disease","category":"indication"},{"label":"CSL Behring GmbH","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Headache","drugRate":"1.8%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"1.8%","severity":"common","organSystem":""},{"effect":"Hypersensitivity","drugRate":"0.9%","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"0.9%","severity":"common","organSystem":""},{"effect":"Eczema","drugRate":"0.9%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Factor IX inhibitor development","drugRate":"8.3%","severity":"serious"}]},"trials":[],"aliases":[],"company":"CSL Behring GmbH","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALBUTREPENONACOG ALFA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:20:09.762166+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Albutrepenonacog Alfa","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:20:23.778271+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:20:22.174105+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:20:09.781115+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALBUTREPENONACOG ALFA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:20:22.805205+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Coagulation factor IX exogenous protein","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:20:23.777807+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5315076/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:20:23.685715+00:00"}},"allNames":"idelvion","offLabel":[],"synonyms":["albutrepenonacog alfa","idelvion"],"timeline":[{"date":"2016-09-28","type":"positive","source":"DrugCentral","milestone":"PMDA approval (CSL Behring K.K.)"},{"date":"2016-11-05","type":"positive","source":"DrugCentral","milestone":"EMA approval (CSL Behring GmbH)"}],"aiSummary":"Idelvion (Albutrepennonacog alfa) is a recombinant coagulation factor IX-FVIII complex, originally developed by CSL Behring GmbH and currently owned by the same company. It is used to treat Hereditary factor IX deficiency disease. Idelvion is administered via injection and is not a small molecule, but rather a protein-based therapy. It is not off-patent and its commercial status is patented. Key safety considerations include potential for thromboembolic events and hypersensitivity reactions.","brandName":"Idelvion","ecosystem":[{"indication":"Hereditary factor IX deficiency disease","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Idelvion is a recombinant coagulation factor IX-FVIII complex, consisting of a fusion protein of factor IX and factor VIII, which is designed to mimic the natural coagulation cascade and promote hemostasis in patients with hereditary factor IX deficiency disease."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Factor_IX","title":"Factor IX","extract":"Factor IX is one of the serine proteases involved in coagulation; it belongs to peptidase family S1. Deficiency of this protein causes haemophilia B."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5189","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ALBUTREPENONACOG%20ALFA","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALBUTREPENONACOG ALFA","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Factor_IX","fields":["history","overview"],"source":"Wikipedia"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T08:33:52.044384","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:20:25.523218+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"albutrepenonacog alfa","indications":{"approved":[{"name":"Hereditary factor IX deficiency disease","source":"DrugCentral","snomedId":41788008,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06399289","phase":"PHASE3","title":"Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSL Behring","startDate":"2024-07-28","conditions":["Hemophilia B"],"enrollment":23,"completionDate":"2026-12-01"},{"nctId":"NCT05086575","phase":"","title":"Observatory of Patients With Haemophilia B Treated by IdElvion®","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSL Behring","startDate":"2021-12-03","conditions":["Haemophilia B"],"enrollment":222,"completionDate":"2027-12"},{"nctId":"NCT02053792","phase":"PHASE3","title":"A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-02-06","conditions":["Hemophilia B"],"enrollment":97,"completionDate":"2021-06-02"},{"nctId":"NCT02546622","phase":"","title":"ATHN 2: Factor Switching Study","status":"COMPLETED","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2015-09","conditions":["Hemophilia"],"enrollment":310,"completionDate":"2020-06-30"},{"nctId":"NCT04108260","phase":"PHASE4","title":"The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2020-04-21","conditions":["Hemophilia"],"enrollment":5,"completionDate":"2022-04"},{"nctId":"NCT01361126","phase":"PHASE1,PHASE2","title":"A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-07","conditions":["Hemophilia B"],"enrollment":17,"completionDate":"2012-07"},{"nctId":"NCT01496274","phase":"PHASE2,PHASE3","title":"A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-02","conditions":["Hemophilia B"],"enrollment":63,"completionDate":""},{"nctId":"NCT01662531","phase":"PHASE3","title":"A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2013-01","conditions":["Hemophilia B"],"enrollment":27,"completionDate":""}],"_emaApprovals":[{"date":"2016-11-05","status":"Authorised","company":"CSL Behring GmbH"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"241551","UNII":"A57KX1VL5P","INN_ID":"9700","RXNORM":"1743992","UMLSCUI":"C4084478","chemblId":"CHEMBL5315076","KEGG_DRUG":"D10770","DRUGBANK_ID":"DB13884","SNOMEDCT_US":"718928008","MESH_SUPPLEMENTAL_RECORD_UI":"C000618231"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"CSL Behring GmbH","relationship":"Current Owner"},{"period":"2016","companyName":"CSL Behring K.K.","relationship":"PMDA Licensee"}],"publicationCount":14,"therapeuticAreas":["Rare Disease"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Aug","pmid":"40176382","title":"Performance of a Drug-Specific Calibration Curve for Monitoring Treatment With Albutrepenonacog Alfa: A Multicenter Study in Argentina.","journal":"International journal of laboratory hematology"},{"date":"2024 Feb","pmid":"38070040","title":"Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.","journal":"Advances in therapy"},{"date":"2023 Dec","pmid":"37680021","title":"Benefits of rIX-FP prophylaxis in patients with Haemophilia B: real-world evidence from a Spanish reference centre.","journal":"Hematology (Amsterdam, Netherlands)"},{"date":"2023 Sep 1","pmid":"37522479","title":"Switching and increasing prophylaxis regimen with a genetically recombinant fusion of coagulation factor IX and albumin in haemophilia B: a case report.","journal":"Current opinion in hematology"},{"date":"2023 Jun","pmid":"37323270","title":"Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa (rIX-FP): A case report.","journal":"Clinical case reports"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"CSL Behring GmbH","companyId":"csl-behring-gmbh","modality":"Recombinant protein","firstApprovalDate":"2016","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:20:25.523218+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}